Natalizumab Elan Pharma
Country: European Union
Language: English
Source: EMA (European Medicines Agency)
Public Assessment Report
(PAR)
25-01-2008
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
natalizumab
Available from:
Elan Pharma International Ltd.
ATC code:
L03AD
INN (International Name):
natalizumab
Therapeutic group:
Immunostimulants,
Therapeutic area:
Crohn Disease
Therapeutic indications:
Treatment of moderately to severely active Crohn's disease for the reduction of signs and symptoms, and the induction and maintenance of sustained response and remission, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or are intolerant to or have medical contraindications to such therapies.
Authorization status:
Refused
